Literature DB >> 17432923

Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Ayman M Noreddin1, Virginia Haynes.   

Abstract

Throughout most of the world we are witnessing an ever increasing number of aged people as a percentage of the general population. In the coming years, the unique spectrum of infections presented by an elderly population, particularly those in long-term care facilities, will challenge our ability to maintain an effective battery of antibacterials. The pharmacokinetic parameters of most antibacterial agents are altered when assessed in the elderly due in part to non-pathological physiological changes. The inability to clear a drug from the body due to declining lung, kidney/bladder, gastrointestinal and circulatory efficiency can cause accumulation in the body of drugs given in standard dosages. While this may have the potential benefit of achieving therapeutic concentrations at a lower dose, there is also a heightened risk of attaining toxic drug concentrations and an increased chance of unfavourable interactions with other medications. Pharmacodynamic issues in the elderly are related to problems that arise from treating elderly patients who may have a history of previous antibacterial treatment and exposure to resistant organisms from multiple hospitalisations. Furthermore, the elderly often acquire infections in tandem with other common disease states such as diabetes mellitus and heart disease. Thus, it is essential that optimised dosage strategies be designed specifically for this population using pharmacodynamic principles that take into account the unique circumstances of the elderly. Rational and effective dosage and administration strategies based on pharmacodynamic breakpoints and detailed understanding of the pharmacokinetics of antibacterials in the elderly increase the chances of achieving complete eradication of an infection in a timely manner. In addition, this strategy helps prevent selection of drug-resistant bacteria and minimises the toxic effects of antibacterial therapy in the elderly patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17432923     DOI: 10.2165/00002512-200724040-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  112 in total

1.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 2.  Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance.

Authors:  C Andrew DeRyke; Su Young Lee; Joseph L Kuti; David P Nicolau
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 3.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.

Authors:  Johan W Mouton; Michael N Dudley; Otto Cars; Hartmut Derendorf; George L Drusano
Journal:  J Antimicrob Chemother       Date:  2005-03-16       Impact factor: 5.790

4.  A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.

Authors:  Joel Morganroth; John P Dimarco; Antonio Anzueto; Michael S Niederman; Shurjeel Choudhri
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

5.  Linezolid penetration into osteo-articular tissues.

Authors:  B Rana; I Butcher; P Grigoris; C Murnaghan; R A Seaton; C M Tobin
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

6.  Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.

Authors:  M J Rybak; B J Abate; S L Kang; M J Ruffing; S A Lerner; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 7.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

8.  Clarithromycin pharmacokinetics in healthy young and elderly volunteers.

Authors:  S Y Chu; D S Wilson; D R Guay; C Craft
Journal:  J Clin Pharmacol       Date:  1992-11       Impact factor: 3.126

9.  Intrapulmonary penetration of linezolid.

Authors:  David Honeybourne; Caroline Tobin; Gail Jevons; Jenny Andrews; Richard Wise
Journal:  J Antimicrob Chemother       Date:  2003-05-13       Impact factor: 5.790

10.  Outpatient gatifloxacin therapy and dysglycemia in older adults.

Authors:  Laura Y Park-Wyllie; David N Juurlink; Alexander Kopp; Baiju R Shah; Therese A Stukel; Carmine Stumpo; Linda Dresser; Donald E Low; Muhammad M Mamdani
Journal:  N Engl J Med       Date:  2006-03-01       Impact factor: 91.245

View more
  3 in total

1.  Transcriptome analysis of murine thymocytes reveals age-associated changes in thymic gene expression.

Authors:  Ana Lustig; Arnell Carter; Dorothy Bertak; Divya Enika; Bolormaa Vandanmagsar; William Wood; Kevin G Becker; Ashani T Weeraratna; Dennis D Taub
Journal:  Int J Med Sci       Date:  2009-02-09       Impact factor: 3.738

Review 2.  Review of antimicrobial use and considerations in the elderly population.

Authors:  Angela Giarratano; Samantha El Green; David P Nicolau
Journal:  Clin Interv Aging       Date:  2018-04-17       Impact factor: 4.458

3.  [Integral approach to the acute exacerbation of chronic obstructive pulmonary disease].

Authors:  J González Del Castillo; F J Candel; J de la Fuente; F Gordo; F J Martín-Sánchez; R Menéndez; A Mujal; J Barberán
Journal:  Rev Esp Quimioter       Date:  2018-10-04       Impact factor: 1.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.